A Phase 3 interventional study of Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg) and Aclidinium bromide 400 μg (AB 400 μg) in Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 163 sites in 10 countries. Open to participants aged 40 Years to 130 Years. Per ClinicalTrials.gov, last updated 2018-11-09.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing aclidinium bromide in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. aclidinium bromide · Pulmonary Disease, Chronic Obstructive.
Among the 28 studies testing aclidinium bromide in Pulmonary Disease, Chronic Obstructive, this one is the 5th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2016, is one of 19 in phase 3, and was the 25th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →None of the 28 studies testing aclidinium bromide in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →
aclidinium bromide: first FDA approval 2012 (TUDORZA PRESSAIR), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,595 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 561 across the 27 interventional studies. Of the 27 that completed or were terminated, 23 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 28 have an industry lead sponsor. The 4 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca: 14 open now, 15 under way, 4 of them phase 3. Of 264 finished, 127 (48%) have results posted.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 20th largest by enrollment of the 194 interventional ones that give a count, is one of 20 that started in 2016, is one of 76 in phase 3, and was the 186th registered.
AstraZeneca’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing aclidinium bromide in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 284 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
This is a multiple dose, randomized, parallel, double-blind, double-dummy, multicenter and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide 400μg/Formoterol Fumarate (AB/FF) 12 μg compared to individual components and TIO (Tiotropium) 18 μg when administered to patients with stable chronic obstructive pulmonary disease (COPD).
This study was conducted to assess the bronchodilator efficacy and safety as well as effect on health related quality of life of AB/FF 400/12 μg compared to the individual components (AB 400 μg and FF 12 μg) in COPD patients. The trial duration of 24 weeks allows the assessment of the effect on symptoms improvement of the combined treatments versus individual components as well as the long term bronchodilation comparison between AB 400 μg and TIO 18 μg in minimizing the risk of COPD exacerbations in current or former smokers, aged ≥40 in symptomatic COPD patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were administered AB/FF 400/12 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.
Drug: Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg) · Other: Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg
Participants were administered AB 400 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.
Drug: Aclidinium bromide 400 μg (AB 400 μg) · Other: Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg
Participants were administered FF 12 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.
Drug: Formoterol fumarate 12 μg (FF 12 μg) · Other: Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg
Participants were administered TIO 18 μg via Handihaler® inhale once daily for 24 weeks of treatment.
Drug: Tiotropium 18 μg (TIO 18 μg) · Other: Placebo to TIO 18 μg
Drug page: Aclidinium bromide
Inhalation powder
Also known as: Oral Inhalation (by Pressair®/Genuair® Dry Powder Inhaler)
Inhalation powder
Also known as: Oral Inhalation (by Pressair®/Genuair® Dry Powder Inhaler)
Inhalation powder
Also known as: Oral Inhalation (by Pressair®/Genuair® Dry Powder Inhaler)
Inhalation powder
Also known as: Oral Inhalation (by Pressair®/Genuair® Dry Powder Inhaler)
Powder in capsules for oral inhalation
Also known as: Oral Inhalation (by Handihaler® Dry Powder Inhaler, DPI)
Powder in capsules for oral inhalation
Also known as: Oral Inhalation (by Handihaler® Dry Powder Inhaler, DPI)
Change From Baseline in 1-hour Morning Post-dose Dose Forced Expiratory Volume in 1 Second (FEV1) of AB/FF 400/12 μg Compared to AB 400 μg at Week 24
To assess the bronchodilatory effect by evaluating the mean changes from baseline in FEV1 at 1 hour post-dose of AB/FF 400/12 µg compared to AB 400 μg after administration of oral inhalation powder BID via DIP to participants with COPD. Baseline was defined as the average of the two FEV1 values measured just prior to the administration of the first dose of investigational product (IP) at randomization Visit. If one of the two was missing, then the available one would be used as baseline value.
Time frame: At baseline 1-hour postdose and Week 24
Change From Baseline in Morning Predose (Trough) FEV1 of AB/FF 400/12 μg Compared to FF 12 μg at Week 24
To assess the bronchodilatory effect by evaluating the mean changes from baseline in FEV1 in morning pre-dose (trough) of AB/FF 400/12 µg compared to FF 12 μg after administration of oral inhalation powder BID via DPI to participants with COPD. Morning pre-dose (trough) FEV1 was defined as the average of the corresponding -30 minute and 0 minute before the morning study medication at Week 24. If one time-point was missing then the available one would be used as morning pre-dose.
Time frame: At baseline morning predose and Week 24
Change From Baseline in Morning Predose (Trough) FEV1 at Week 24 Comparing AB 400 μg Versus TIO 18 μg to Demonstrate Non-inferiority
To assess the non-inferior bronchodilatory effect by evaluating the mean changes from baseline in FEV1 in morning pre-dose (trough)of AB 400 µg compared to TIO 18 μg after administration of oral inhalation powder BID via DPI to participants with COPD.
Time frame: At baseline morning predose and Week 24
Change From Baseline in Normalized Area Under Curve 3hours Post-dose (nAUC0-3/3h) FEV1 of AB/FF 400/12 μg Compared to AB 400 μg and and FF 12 μg at Week 24
To assess the bronchodilatory effect by evaluating the mean changes from baseline in nAUC0-3/3h FEV1 of AB/FF 400/12 µg compared to AB 400 μg and and FF 12 μg after administration of oral inhalation powder BID via DPI to participants with COPD.
Time frame: At Day 1 and Day 169
Responder (Number of Participants) Analysis of St. George's Respiratory Questionnaire (SGRQ) Total Score With AB/FF 400/12 μg Versus AB 400 μg and FF 12 μg.
SGRQ was a A standardized self-completed tool used to measure impaired health and perceived well-being ("quality of life") in respiratory diseases. The questionnaire contained 50 items divided into 3 (symptoms, activity and impacts) dimensions. Each of the three dimensions of the questionnaire is scored separately in the range from 0 to 100%, zero score indicating no impairment of life quality. A summary score utilizing responses to all items is the total SGRQ score which also ranges from 0 to 100%. The SGRQ scores are calculated using weights attached to each item of the questionnaire which provides an estimate of the distress associated with the symptoms or state described in each item. Higher scores indicate poorer health. A decrease of at least 4 units in the SGRQ total score has been established as the criterion for minimal meaningful improvement. SGRQ responders will be those with a decrease in SGRQ total score of at least 4 units from baseline.
Time frame: At baseline and Week 24
Study was conducted on participants with stable chronic obstructive pulmonary disease (COPD), in 11 countries: United States (US), Germany, Poland, Hungary, Bulgaria, Ukraine, United Kingdom (UK), Czech Republic, Spain, Israel \& Russia (was not finally started). First participant enrolled was 05 July 2016 \& participant last visit was 08 June 2017
| Milestone | Aclidinium Bromide (AB)/Formoterol Fumarate (FF) 400/12 μg | AB 400 μg | FF 12 μg | Tiotropium (TIO) 18 μg |
|---|---|---|---|---|
| Started | 317 | 478 | 320 | 479 |
| Completed treatment and follow-up | 279 | 405 | 267 | 403 |
| Completed | 279 | 405 | 267 | 405 |
| Not completed | 38 | 73 | 53 | 74 |
| Withdrew: Adverse event | 11 | 22 | 14 | 14 |
| Withdrew: Protocol violation | 7 | 5 | 4 | 8 |
| Withdrew: Lost to follow-up | 1 | 5 | 2 | 2 |
| Withdrew: Lack of efficacy | 7 | 9 | 14 | 20 |
| Withdrew: Withdrawal by subject | 4 | 14 | 6 | 7 |
| Withdrew: Progressive disease | 6 | 15 | 13 | 18 |
| Withdrew: Reason not mentioned | 2 | 3 | 0 | 5 |
To assess the bronchodilatory effect by evaluating the mean changes from baseline in FEV1 at 1 hour post-dose of AB/FF 400/12 µg compared to AB 400 μg after administration of oral inhalation powder BID via DIP to participants with COPD. Baseline was defined as the average of the two FEV1 values measured just prior to the administration of the first dose of investigational product (IP) at randomization Visit. If one of the two was missing, then the available one would be used as baseline value.
| Litres | AB/FF 400/12 μg | AB 400 μg | FF 12 μg | TIO 18 μg |
|---|---|---|---|---|
| Change From Baseline in 1-hour Morning Post-dose Dose Forced Expiratory Volume in 1 Second (FEV1) of AB/FF 400/12 μg Compared to AB 400 μg at Week 24 | 0.253 ± 0.013 | 0.169 ± 0.011 | 0.168 ± 0.013 | 0.161 ± 0.011 |
To assess the bronchodilatory effect by evaluating the mean changes from baseline in FEV1 in morning pre-dose (trough) of AB/FF 400/12 µg compared to FF 12 μg after administration of oral inhalation powder BID via DPI to participants with COPD. Morning pre-dose (trough) FEV1 was defined as the average of the corresponding -30 minute and 0 minute before the morning study medication at Week 24. If one time-point was missing then the available one would be used as morning pre-dose.
| Litres | AB/FF 400/12 μg | AB 400 μg | FF 12 μg | TIO 18 μg |
|---|---|---|---|---|
| Change From Baseline in Morning Predose (Trough) FEV1 of AB/FF 400/12 μg Compared to FF 12 μg at Week 24 | 0.080 ± 0.014 | 0.066 ± 0.012 | 0.025 ± 0.014 | 0.060 ± 0.012 |
To assess the non-inferior bronchodilatory effect by evaluating the mean changes from baseline in FEV1 in morning pre-dose (trough)of AB 400 µg compared to TIO 18 μg after administration of oral inhalation powder BID via DPI to participants with COPD.
| Litres | AB 400 μg | TIO 18 μg |
|---|---|---|
| Change From Baseline in Morning Predose (Trough) FEV1 at Week 24 Comparing AB 400 μg Versus TIO 18 μg to Demonstrate Non-inferiority | 0.064 ± 0.013 | 0.057 ± 0.013 |
To assess the bronchodilatory effect by evaluating the mean changes from baseline in nAUC0-3/3h FEV1 of AB/FF 400/12 µg compared to AB 400 μg and and FF 12 μg after administration of oral inhalation powder BID via DPI to participants with COPD.
| Litres | AB/FF 400/12 μg | AB 400 μg | FF 12 μg | TIO 18 μg |
|---|---|---|---|---|
| Change From Baseline in Normalized Area Under Curve 3hours Post-dose (nAUC0-3/3h) FEV1 of AB/FF 400/12 μg Compared to AB 400 μg and and FF 12 μg at Week 24 | 0.237 ± 0.013 | 0.162 ± 0.010 | 0.149 ± 0.013 | 0.151 ± 0.010 |
SGRQ was a A standardized self-completed tool used to measure impaired health and perceived well-being ("quality of life") in respiratory diseases. The questionnaire contained 50 items divided into 3 (symptoms, activity and impacts) dimensions. Each of the three dimensions of the questionnaire is scored separately in the range from 0 to 100%, zero score indicating no impairment of life quality. A summary score utilizing responses to all items is the total SGRQ score which also ranges from 0 to 100%. The SGRQ scores are calculated using weights attached to each item of the questionnaire which provides an estimate of the distress associated with the symptoms or state described in each item. Higher scores indicate poorer health. A decrease of at least 4 units in the SGRQ total score has been established as the criterion for minimal meaningful improvement. SGRQ responders will be those with a decrease in SGRQ total score of at least 4 units from baseline.
| Participants | AB/FF 400/12 μg | AB 400 μg | FF 12 μg | TIO 18 μg |
|---|---|---|---|---|
| Number of responders -Yes | 130 | 188 | 128 | 197 |
| Number of responders- NO | 140 | 195 | 130 | 192 |
Collected over From time of signature of the ICF throughout the treatment period and including the follow-up period (14 days after the last study drug administration). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AB/FF 400/12 μg | 1/314 (0.3%) | 23/314 (7.3%) | 173/314 (55.1%) |
| AB 400 μg | 1/475 (0.2%) | 41/475 (8.6%) | 222/475 (46.7%) |
| FF 12 μg | 4/319 (1.3%) | 22/319 (6.9%) | 178/319 (55.8%) |
| TIO 18 μg | 2/475 (0.4%) | 37/475 (7.8%) | 241/475 (50.7%) |
| Event | AB/FF 400/12 μg | AB 400 μg | FF 12 μg | TIO 18 μg |
|---|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 7/314 | 11/475 | 10/319 | 14/475 |
| PneumoniaInfections and infestations | 4/314 | 3/475 | 1/319 | 2/475 |
| Myocardial infarctionCardiac disorders | 0/314 | 0/475 | 0/319 | 3/475 |
| Cardiac failure acuteCardiac disorders | 0/314 | 2/475 | 0/319 | 0/475 |
| Cardiac failure congestiveCardiac disorders | 0/314 | 2/475 | 0/319 | 0/475 |
| Atrial fibrillationCardiac disorders | 0/314 | 1/475 | 0/319 | 2/475 |
| AppendicitisInfections and infestations | 1/314 | 0/475 | 0/319 | 0/475 |
| SepsisInfections and infestations | 1/314 | 0/475 | 0/319 | 0/475 |
| Angina pectorisCardiac disorders | 1/314 | 0/475 | 0/319 | 1/475 |
| Atrial tachycardiaCardiac disorders | 1/314 | 0/475 | 0/319 | 0/475 |
| Event | AB/FF 400/12 μg | AB 400 μg | FF 12 μg | TIO 18 μg |
|---|---|---|---|---|
| Chronic obstructive pulmonaryRespiratory, thoracic and mediastinal disorders | 49/314 | 79/475 | 58/319 | 61/475 |
| NasopharyngitisInfections and infestations | 36/314 | 47/475 | 39/319 | 64/475 |
| HeadacheNervous system disorders | 16/314 | 19/475 | 17/319 | 25/475 |
| Back painMusculoskeletal and connective tissue disorders | 15/314 | 7/475 | 8/319 | 7/475 |
| Upper respiratory tract infectionInfections and infestations | 8/314 | 13/475 | 7/319 | 17/475 |
| CoughRespiratory, thoracic and mediastinal disorders | 6/314 | 7/475 | 4/319 | 17/475 |
| HypertensionVascular disorders | 7/314 | 8/475 | 9/319 | 7/475 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 6/314 | 13/475 | 6/319 | 12/475 |
| SinusitisInfections and infestations | 8/314 | 10/475 | 6/319 | 7/475 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/314 | 4/475 | 3/319 | 8/475 |
| Age, Continuous(Years) | Aclidinium Bromide (AB)/Formoterol Fumarate (FF) 400/12 μg | AB 400 μg | FF 12 μg | Tiotropium (TIO) 18 μg | Total |
|---|---|---|---|---|---|
| Mean | 64.4 ± 8.5 | 64.4 ± 8.1 | 64.7 ± 8.3 | 64.0 ± 8.6 | 64.3 ± 8.4 |
| Sex: Female, Male(Participants) | Aclidinium Bromide (AB)/Formoterol Fumarate (FF) 400/12 μg | AB 400 μg | FF 12 μg | Tiotropium (TIO) 18 μg | Total |
|---|---|---|---|---|---|
| Female | 121 | 171 | 129 | 199 | 620 |
| Male | 193 | 304 | 190 | 276 | 963 |
| Race (NIH/OMB)(Participants) | Aclidinium Bromide (AB)/Formoterol Fumarate (FF) 400/12 μg | AB 400 μg | FF 12 μg | Tiotropium (TIO) 18 μg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 |
| Asian | 0 | 2 | 0 | 2 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 17 | 28 | 16 | 16 | 77 |
| White | 297 | 444 | 303 | 457 | 1501 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
Showing the first 100 of 163 sites across 10 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2016 to primary completion in Jun 2017, 11 months.
Results were first posted in Nov 2018, 1 year 5 months after primary completion.
Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 11 months is below that.
Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Aclidinium bromide · Formoterol · Tiotropium
Pulmonary Disease, Chronic Obstructive →